FMP
Lexaria Bioscience Corp.
LEXX
NASDAQ
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
1.17 USD
-0.05 (-4.27%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
384.54k
722.74k
255.4k
226.21k
464.28k
594.11k
760.24k
972.84k
1.24M
1.59M
Revenue %
-
87.95
-64.66
-11.43
105.24
27.96
27.96
27.96
27.96
Ebitda
-4M
-5.58M
-6.52M
-6.39M
-5.68M
-594.11k
-760.24k
-972.84k
-1.24M
-1.59M
Ebitda %
-1.04k
-771.39
-2.55k
-2.82k
-1.22k
-100
-100
-100
-100
Ebit
-4.15M
-5.72M
-6.66M
-6.53M
-5.75M
-594.11k
-760.24k
-972.84k
-1.24M
-1.59M
Ebit %
-1.08k
-791.81
-2.61k
-2.89k
-1.24k
-100
-100
-100
-100
Depreciation
146.09k
147.6k
146.91k
145.4k
76.15k
233.62k
298.95k
382.55k
489.53k
626.42k
Depreciation %
37.99
20.42
57.52
64.28
16.4
39.32
39.32
39.32
39.32
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
